OLD National Bancorp IN lessened its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 8.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 29,470 shares of the biopharmaceutical company’s stock after selling 2,622 shares during the quarter. OLD National Bancorp IN’s holdings in Gilead Sciences were worth $2,111,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Welch Investments LLC acquired a new position in Gilead Sciences during the 3rd quarter valued at approximately $108,000. Wealthcare Advisory Partners LLC acquired a new position in Gilead Sciences during the 3rd quarter valued at approximately $133,000. Horan Capital Advisors LLC. acquired a new position in Gilead Sciences during the 3rd quarter valued at approximately $144,000. Migdal Insurance & Financial Holdings Ltd. acquired a new position in Gilead Sciences during the 2nd quarter valued at approximately $147,000. Finally, Hanson & Doremus Investment Management increased its stake in Gilead Sciences by 806.5% during the 3rd quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock valued at $147,000 after purchasing an additional 1,613 shares in the last quarter. Hedge funds and other institutional investors own 77.83% of the company’s stock.
Shares of Gilead Sciences, Inc. (NASDAQ GILD) opened at $75.57 on Friday. Gilead Sciences, Inc. has a twelve month low of $63.76 and a twelve month high of $89.54. The stock has a market cap of $100,199.45, a price-to-earnings ratio of 8.96, a P/E/G ratio of -1.76 and a beta of 1.24. The company has a current ratio of 2.74, a quick ratio of 2.67 and a debt-to-equity ratio of 1.53.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.67 by $0.11. Gilead Sciences had a net margin of 17.73% and a return on equity of 50.29%. The firm had revenue of $5.95 billion for the quarter, compared to the consensus estimate of $5.71 billion. During the same period in the prior year, the firm posted $2.70 earnings per share. The firm’s quarterly revenue was down 18.7% compared to the same quarter last year. analysts anticipate that Gilead Sciences, Inc. will post 6.21 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Thursday, March 29th. Investors of record on Friday, March 16th will be issued a dividend of $0.57 per share. The ex-dividend date is Thursday, March 15th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.52. This represents a $2.28 dividend on an annualized basis and a yield of 3.02%. Gilead Sciences’s dividend payout ratio is 65.52%.
A number of research analysts have issued reports on GILD shares. Leerink Swann restated a “market perform” rating and set a $80.00 price target (down previously from $83.00) on shares of Gilead Sciences in a research note on Thursday, February 22nd. Credit Suisse Group reaffirmed a “buy” rating and issued a $82.00 price objective on shares of Gilead Sciences in a report on Thursday, December 7th. Zacks Investment Research downgraded shares of Gilead Sciences from a “hold” rating to a “sell” rating in a report on Wednesday, December 27th. ValuEngine raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Thursday, February 8th. Finally, Wells Fargo raised shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and upped their price objective for the company from $79.02 to $96.00 in a report on Tuesday, January 16th. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $88.61.
In other Gilead Sciences news, insider John C. Martin sold 50,000 shares of the stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $73.62, for a total transaction of $3,681,000.00. Following the transaction, the insider now directly owns 3,046,766 shares of the company’s stock, valued at $224,302,912.92. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Gregg H. Alton sold 15,000 shares of the stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $73.87, for a total transaction of $1,108,050.00. Following the transaction, the executive vice president now directly owns 64,613 shares in the company, valued at $4,772,962.31. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 436,101 shares of company stock worth $34,541,560. Insiders own 1.30% of the company’s stock.
WARNING: This story was published by Transcript Daily and is owned by of Transcript Daily. If you are viewing this story on another site, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this story can be viewed at https://transcriptdaily.com/2018/03/23/gilead-sciences-inc-gild-position-lowered-by-old-national-bancorp-in.html.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.